Month: March 2024

Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma

LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals,...

Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma

Submission supported by data from Phase 3 PERSEUS study, which showed the daratumumab subcutaneous formulation-based regimen significantly reduced the risk...

Innovaccer’s AI-Cloud for Healthcare Ranked No. 1 Population Health Management Solution in the 2024 Black Book User Survey for Third Consecutive Year

Innovaccer receives top ratings from hospital and health system customers in 11 key categories in the 2024 Black Book Population...

Innovaccer’s Data Activation Platform Secures the Leading Position as the Premier End-to-End Population Health Solution in the 2024 Black Book User Survey

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Black Book's thorough investigation into population health data activation platforms...

AliMed Unveils Proprietary Line of Radiation Protection Garments, Managing Full Manufacturing Process for Improved Quality and Timely Delivery

Dedham, Massachusetts--(Newsfile Corp. - March 5, 2024) - AliMed, Inc., a Massachusetts-based medical supply manufacturer and distributor, announced today the...

error: Content is protected !!